181 related articles for article (PubMed ID: 30026439)
1. [Hematologic Malignancies/Pediatric Malignancies New Therapeutic Strategy for Hematologic Malignancies].
Usui N
Gan To Kagaku Ryoho; 2018 May; 45(5):793-794. PubMed ID: 30026439
[No Abstract] [Full Text] [Related]
2. [Hematologic Malignancies/Pediatric Malignancies. Roles of Drugs Approved as New Agents and as Additional Indications for Relapse or Refractory Hematologic Malignancies].
Usui N
Gan To Kagaku Ryoho; 2016 May; 43(5):528-9. PubMed ID: 27344679
[No Abstract] [Full Text] [Related]
3. [Hematologic malignancies /pediatric malignancies-current status of molecular target therapy for hematologic cancer].
Usui N
Gan To Kagaku Ryoho; 2010 May; 37(5):805. PubMed ID: 20524247
[No Abstract] [Full Text] [Related]
4. [Hematologic malignancies/pediatric malignancies].
Usui N
Gan To Kagaku Ryoho; 2012 May; 39(5):731. PubMed ID: 22701898
[No Abstract] [Full Text] [Related]
5. Bendamustine: a new therapeutic option for hematologic malignancies.
Cheson BD
Clin Adv Hematol Oncol; 2008 Sep; 6(9):631-3. PubMed ID: 18827785
[No Abstract] [Full Text] [Related]
6. Arsenic derivatives as therapeutic agents for hematologic malignancies.
Verstovsek S; Estrov Z
Leuk Res; 2004 Sep; 28(9):901-3. PubMed ID: 15234564
[No Abstract] [Full Text] [Related]
7. New targets for hematologic malignancies.
Bradner J
Clin Adv Hematol Oncol; 2013 Jun; 11(6):375-6. PubMed ID: 24472807
[No Abstract] [Full Text] [Related]
8. [A role of new molecular-target drugs for hematologic malignancies].
Usui N
Gan To Kagaku Ryoho; 2015 May; 42(5):548-9. PubMed ID: 26054087
[No Abstract] [Full Text] [Related]
9. [Current issues concerning drug development for pediatric hematologic malignancies].
Sekimizu M
Rinsho Ketsueki; 2016 Jun; 57(6):693-700. PubMed ID: 27384847
[TBL] [Abstract][Full Text] [Related]
10. [Immune-checkpoint inhibitors in hematologic malignancies].
Maruyama D
Rinsho Ketsueki; 2016; 57(11):2381-2387. PubMed ID: 27941289
[TBL] [Abstract][Full Text] [Related]
11. New advances in the treatment of hematologic malignancies: focus on topoisomerase I inhibitors. Introduction.
Kantarjian H
Semin Hematol; 1998 Jul; 35(3 Suppl 4):1-2. PubMed ID: 9779875
[No Abstract] [Full Text] [Related]
12. Farnesyl transferase inhibition in hematologic malignancies.
Karp JE
J Natl Compr Canc Netw; 2005 Nov; 3 Suppl 1():S37-40. PubMed ID: 16280111
[No Abstract] [Full Text] [Related]
13. Assessing the effects of treatments for hematological malignancies on prepubertal growth.
Pearce MS
Pediatr Hematol Oncol; 2000 Sep; 17(6):441-3. PubMed ID: 10989463
[No Abstract] [Full Text] [Related]
14. Drug resistance in hematologic malignancies: induction mechanisms, genetics, and therapeutics.
Zhan F; Zangari M; Qiu L
Biomed Res Int; 2015; 2015():384575. PubMed ID: 26000289
[No Abstract] [Full Text] [Related]
15. [Limitations in application of imatinib in hematologic malignancies: are there new principal solutions?].
Rukavitsyn OA; Pop VP
Ter Arkh; 2008; 80(7):80-4. PubMed ID: 18763606
[No Abstract] [Full Text] [Related]
16. Antibodies and hematologic malignancies.
Smith MR
Cancer J; 2008; 14(3):184-90. PubMed ID: 18536558
[TBL] [Abstract][Full Text] [Related]
17. Evolving role of ribonucleoside reductase inhibitors in hematologic malignancies.
Tsimberidou AM; Alvarado Y; Giles FJ
Expert Rev Anticancer Ther; 2002 Aug; 2(4):437-48. PubMed ID: 12647987
[TBL] [Abstract][Full Text] [Related]
18. Hepatitis C treatment concomitant to chemotherapy as "salvage" therapy in children with hematologic malignancies.
Papaevangelou V; Varsami M; Papadakis V; Zellos A; Parcharidou A; Papargyri S; Karentzou O; Manolaki N; Roma E; Polychronopoulou S
Pediatr Infect Dis J; 2010 Mar; 29(3):277-80. PubMed ID: 19949358
[TBL] [Abstract][Full Text] [Related]
19. Arsenic derivatives in hematologic malignancies: a role beyond acute promyelocytic leukemia?
Verstovsek S; Giles F; Quintás-Cardama A; Perez N; Ravandi-Kashani F; Beran M; Freireich E; Kantarjian H
Hematol Oncol; 2006 Dec; 24(4):181-8. PubMed ID: 16783836
[TBL] [Abstract][Full Text] [Related]
20. Farnesyltransferase inihibitors in hematologic malignancies.
Harousseau JL
Blood Rev; 2007 Jul; 21(4):173-82. PubMed ID: 17293017
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
